Harvard Bioscience (HBIO) Income from Continuing Operations (2010 - 2026)
Harvard Bioscience's (HBIO) quarterly Income from Continuing Operations came in at 3424000.0 in Q1 2026, up 93.19% year-on-year from 1772329.83 in Q1 2025, and down 21.5% on a QoQ basis from 2818000.0 in Q4 2025.
Harvard Bioscience (HBIO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Income from Continuing Operations data on file, last reported at 3424000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 93.19% year-over-year to 3424000.0 in Q1 2026; TTM through Mar 2026 was 9757000.0, a 83.08% increase from a year earlier, with the FY2025 full-year figure at 56700000.0, down 368.79% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3424000.0, down from 2818000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for HBIO reached as high as 2421000.0 in Q2 2022 and fell as low as 50294000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 4927470.59 across 5 years, with a median of 2284000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 660.42% in 2022 and fell as far as 1902.94% in 2022.
- Year by year, Income from Continuing Operations stood at 1666000.0 in 2022, then surged by 72.03% to 466000.0 in 2023, then jumped by 177.25% to 360000.0 in 2024, then tumbled by 882.78% to 2818000.0 in 2025, then slipped by 21.5% to 3424000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 3424000.0 in Q1 2026, 2818000.0 in Q4 2025, and 1231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 240.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -37.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 13.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Harvard Bioscience | 28.05 Mn | 20.96 Mn | 12.24 Mn | -3.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.42 Mn |
| Dec 31, 2025 | -2.82 Mn |
| Sep 30, 2025 | -1.23 Mn |
| Jun 30, 2025 | -2.28 Mn |
| Mar 31, 2025 | -50.29 Mn |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -2.93 Mn |
| Mar 31, 2024 | -4.69 Mn |
| Dec 31, 2023 | -466,000.00 |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -998,000.00 |
| Mar 31, 2023 | 607,000.00 |
| Dec 31, 2022 | -1.67 Mn |
| Sep 30, 2022 | -3.41 Mn |
| Jun 30, 2022 | 2.42 Mn |
| Mar 31, 2022 | -6.92 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | -170,000.00 |
| Jun 30, 2021 | -432,000.00 |